Polymeric conjugates for drug delivery.
暂无分享,去创建一个
[1] A. Ray,et al. HPMA Copolymer-Aminohexylgeldanamycin Conjugates Targeting Cell Surface Expressed GRP78 in Prostate Cancer , 2010, Pharmaceutical Research.
[2] K. Ulbrich,et al. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[3] C. Peterson,et al. Antitumor efficacy of colon-specific HPMA copolymer/9-aminocamptothecin conjugates in mice bearing human-colon carcinoma xenografts. , 2009, Macromolecular bioscience.
[4] Q. Teng,et al. Design and evaluation of micellar nanocarriers for 17-allyamino-17-demethoxygeldanamycin (17-AAG). , 2010, International journal of pharmaceutics.
[5] N. K. Jain,et al. Dendrimers as therapeutic agents: a systematic review , 2009 .
[6] Paul Debbage,et al. Targeted drugs and nanomedicine: present and future. , 2009, Current pharmaceutical design.
[7] P. Zahedi,et al. Polymeric drug delivery systems for localized cancer chemotherapy , 2010, Drug delivery.
[8] Tongwen Xu,et al. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. , 2011, Chemical Society reviews.
[9] A. Tolcher,et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Simona Jevševar,et al. PEGylation of therapeutic proteins , 2010, Biotechnology journal.
[11] Alexander V Kabanov,et al. Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[12] Kazunori Kataoka,et al. Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. , 2005, Bioconjugate chemistry.
[13] S. Perrier,et al. Bioapplications of RAFT polymerization. , 2009, Chemical reviews.
[14] Xue Ying,et al. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. , 2011, Biomaterials.
[15] V. Torchilin,et al. Micellar Nanocarriers: Pharmaceutical Perspectives , 2006, Pharmaceutical Research.
[16] Jonathan R. McDaniel,et al. Drug delivery to solid tumors by elastin-like polypeptides. , 2010, Advanced drug delivery reviews.
[17] J. Kopeček,et al. Coiled-coil based drug-free macromolecular therapeutics: in vivo efficacy. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[18] R. Kannan,et al. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. , 2010, Drug discovery today.
[19] A. Ray,et al. Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates. , 2011, Molecular pharmaceutics.
[20] Vladimir P Torchilin,et al. Passive and active drug targeting: drug delivery to tumors as an example. , 2010, Handbook of experimental pharmacology.
[21] Lei Yu,et al. Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate , 2010, International journal of nanomedicine.
[22] S. Balu-Iyer,et al. Delivery of therapeutic proteins. , 2010, Journal of pharmaceutical sciences.
[23] Michael B. Hall,et al. Dendritic macromolecules: synthesis of starburst dendrimers , 1986 .
[24] J. Schellens,et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel , 2001, Anti-cancer drugs.
[25] Francesco M Veronese,et al. Anti-cancer PEG-enzymes: 30 years old, but still a current approach. , 2008, Advanced drug delivery reviews.
[26] H. Dai,et al. PEG branched polymer for functionalization of nanomaterials with ultralong blood circulation. , 2009, Journal of the American Chemical Society.
[27] H. Ghandehari,et al. HPMA copolymer-cyclic RGD conjugates for tumor targeting. , 2010, Advanced drug delivery reviews.
[28] U. Schubert,et al. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. , 2010, Angewandte Chemie.
[29] Atsushi Harada,et al. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. , 2003, Angewandte Chemie.
[30] Michael Jay,et al. Polymer Micelles with Hydrazone-Ester Dual Linkers for Tunable Release of Dexamethasone , 2011, Pharmaceutical Research.
[31] Y. Shaked,et al. Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. , 2011, Molecular pharmaceutics.
[32] R. Fram,et al. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. , 2009, Advanced drug delivery reviews.
[33] F. Veronese,et al. PEGylation for improving the effectiveness of therapeutic biomolecules. , 2009, Drugs of today.
[34] M. Socinski,et al. Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[35] K. Fu,et al. Synthesis and Evaluation of a Well-defined HPMA Copolymer–Dexamethasone Conjugate for Effective Treatment of Rheumatoid Arthritis , 2008, Pharmaceutical Research.
[36] A. Ray,et al. PAMAM-Camptothecin Conjugate Inhibits Proliferation and Induces Nuclear Fragmentation in Colorectal Carcinoma Cells , 2010, Pharmaceutical Research.
[37] H. Ghandehari,et al. Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery. , 2012, Advanced drug delivery reviews.
[38] Scott H. Medina,et al. Dendrimers as carriers for delivery of chemotherapeutic agents. , 2009, Chemical reviews.
[39] S. Wołowiec,et al. Solubility and in vitro transdermal diffusion of riboflavin assisted by PAMAM dendrimers. , 2011, International journal of pharmaceutics.
[40] Kinam Park,et al. Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[41] H. Ghandehari,et al. A prostate-specific antigen–activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer , 2007, Molecular Cancer Therapeutics.
[42] Yiguang Jin,et al. A 5-fluorouracil-loaded pH-responsive dendrimer nanocarrier for tumor targeting. , 2011, International journal of pharmaceutics.
[43] Bo Yu,et al. Receptor-targeted nanocarriers for therapeutic delivery to cancer , 2010, Molecular membrane biology.
[44] C. van Nostrum,et al. Synthesis and applications of biomedical and pharmaceutical polymers via click chemistry methodologies. , 2009, Bioconjugate chemistry.
[45] T. Lammers. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. , 2010, Advanced drug delivery reviews.
[46] W. Guo,et al. Endosomal pH-activatable poly(ethylene oxide)-graft-doxorubicin prodrugs: synthesis, drug release, and biodistribution in tumor-bearing mice. , 2011, Biomacromolecules.
[47] K. Ulbrich,et al. New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[48] J. Singer,et al. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer–drug conjugate , 2006, International journal of nanomedicine.
[49] Y. Bae,et al. Reconstitutable charged polymeric (PLGA)(2)-b-PEI micelles for gene therapeutics delivery. , 2011, Biomaterials.
[50] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[51] J. Schellens,et al. A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors , 2004, Clinical Cancer Research.
[52] Thommey P. Thomas,et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. , 2005, Cancer research.
[53] K. Ulbrich,et al. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. , 2009, Biomaterials.
[54] V. Torchilin,et al. Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. , 2008, Nanomedicine.
[55] Reynier Báez,et al. PEGylated Interferon-α2b: A Branched 40K Polyethylene Glycol Derivative , 2005, Pharmaceutical Research.
[56] Vladimir Torchilin,et al. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[57] D. Kerr,et al. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[58] J. Kopeček,et al. Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[59] J. Haveman,et al. The relevance of tumour pH to the treatment of malignant disease. , 1984, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[60] A. Secord,et al. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. , 2008, Gynecologic oncology.
[61] R. J. Green,et al. Polymer-drug conjugates for combination anticancer therapy: investigating the mechanism of action. , 2009, Journal of medicinal chemistry.
[62] Aaron D Baldwin,et al. Polysaccharide‐modified synthetic polymeric biomaterials , 2010, Biopolymers.
[63] Andrew Becker,et al. Methotrexate delivery via folate targeted dendrimer-based nanotherapeutic platform. , 2009, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.
[64] W. Hennink,et al. A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. , 2003, Bioconjugate chemistry.
[65] James R. Dewald,et al. A New Class of Polymers: Starburst-Dendritic Macromolecules , 1985 .
[66] M. Hershfield,et al. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. , 1988, The Journal of pediatrics.
[67] D. Tomalia,et al. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. , 2001, Drug discovery today.
[68] J. Schellens,et al. Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients , 2007, Cancer Chemotherapy and Pharmacology.
[69] H. Maeda,et al. Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.
[70] Jean M. J. Fréchet,et al. Dendrimers and supramolecular chemistry , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[71] Andrew T. Russell,et al. Self-immolative linkers in polymeric delivery systems , 2011 .
[72] M. Zamai,et al. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[73] Zhi-xin Xu,et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. , 2001, Bioconjugate chemistry.
[74] Ruixia Chen,et al. Degradation and degradation-induced re-assembly of PVP-PCL micelles. , 2010, Biomacromolecules.
[75] C. van Nostrum,et al. Micelles based on HPMA copolymers. , 2010, Advanced drug delivery reviews.
[76] H. Groen,et al. A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours , 2004, British Journal of Cancer.
[77] Ruth Duncan,et al. Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. , 2009, Advanced drug delivery reviews.
[78] John Samuel,et al. Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery. , 2002, Advanced drug delivery reviews.
[79] Thommey P. Thomas,et al. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. , 2005, Journal of medicinal chemistry.
[80] Kazunori Kataoka,et al. Block copolymer micelles for delivery of gene and related compounds. , 2002, Advanced drug delivery reviews.
[81] Véronique Préat,et al. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[82] Deborah S. Goldberg,et al. G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[83] Hisataka Kobayashi,et al. Dendrimer-based contrast agents for molecular imaging. , 2008, Current topics in medicinal chemistry.
[84] V. Šubr,et al. Cleavage of oligopeptide side-chains in N-(2-hydroxypropyl)meth-acrylamide copolymers by mixtures of lysosomal enzymes☆ , 1988 .
[85] H. Ringsdorf. Structure and properties of pharmacologically active polymers , 1975 .
[86] M. Vicent,et al. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. , 2010, Advanced drug delivery reviews.
[87] Y. Tsutsumi,et al. Antitumor Activity of Tumor Necrosis Factor-α Conjugated with Polyvinylpyrrolidone on Solid Tumors in Mice , 2000 .
[88] J. Feijen,et al. α-Amino acid containing degradable polymers as functional biomaterials: rational design, synthetic pathway, and biomedical applications. , 2011, Biomacromolecules.
[89] Karl Fischer,et al. Temperature triggered self-assembly of polypeptides into multivalent spherical micelles. , 2008, Journal of the American Chemical Society.
[90] J. Kopeček,et al. Synthesis of Biodegradable Multiblock Copolymers by Click Coupling of RAFT-Generated HeterotelechelicPolyHPMA Conjugates. , 2011, Reactive & functional polymers.
[91] J. Kopeček. Controlled biodegradability of polymers--a key to drug delivery systems. , 1984, Biomaterials.
[92] Hiroshi Maeda,et al. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. , 2010, Bioconjugate chemistry.
[93] Y. Pommier. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. , 2009, Chemical reviews.
[94] Michel Vert,et al. Peptide-poly(L-lysine citramide) conjugates and their in vitro anti-HIV behavior. , 2009, Biomacromolecules.
[95] H. Maeda,et al. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[96] P. Shewry,et al. Elastomeric proteins: biological roles, structures and mechanisms. , 2000, Trends in biochemical sciences.
[97] J. Kemp,et al. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor. , 1995, Cancer research.
[98] David Putnam,et al. Polymer conjugates with anticancer activity , 1995 .
[99] Jun Fang,et al. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.
[100] J. Kopeček,et al. Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs. , 2008, International journal of pharmaceutics.
[101] Lei Zhu,et al. Synthesis and in vitro cancer cell targeting of folate-functionalized biodegradable amphiphilic dendrimer-like star polymers. , 2010, Biomacromolecules.
[102] L. Gerweck,et al. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. , 1996, Cancer research.
[103] C. Takimoto,et al. Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies , 2009, Cancer Chemotherapy and Pharmacology.
[104] F. Szoka,et al. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas , 2006, Proceedings of the National Academy of Sciences.
[105] J. Kopeček,et al. Synthesis and characterization of poly(ε-caprolactone)-block-poly[N-(2-hydroxypropyl)methacrylamide] micelles for drug delivery. , 2011, Macromolecular bioscience.
[106] Y. Chau,et al. Synthesis, characterization, and in vivo evaluation of poly(ethylene oxide-co-glycidol)-platinate conjugate. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[107] E. Sausville,et al. Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery. , 2009, Molecular pharmaceutics.
[108] S. Jain,et al. A PEGylated dendritic nanoparticulate carrier of fluorouracil. , 2003, International journal of pharmaceutics.
[109] Krzysztof Matyjaszewski,et al. Nanostructured functional materials prepared by atom transfer radical polymerization , 2009, Nature Chemistry.
[110] M. Vicent,et al. HPMA Copolymer-1,5-Diazaanthraquinone Conjugates as Novel Anticancer Therapeutics , 2004, Journal of drug targeting.
[111] Malar A. Azagarsamy,et al. Guest-release control in enzyme-sensitive, amphiphilic-dendrimer-based nanoparticles through photochemical crosslinking. , 2011, Chemistry.
[112] V. Pillay,et al. Stimuli-responsive polymers and their applications in drug delivery , 2009, Biomedical materials.
[113] Gianfranco Pasut,et al. PEG conjugates in clinical development or use as anticancer agents: an overview. , 2009, Advanced drug delivery reviews.
[114] N. Vorsa,et al. Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. , 2006, Bioconjugate chemistry.
[115] K. Ulbrich,et al. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. , 1994, British Journal of Cancer.
[116] Hong Zhao,et al. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. , 2008, Bioconjugate chemistry.
[117] R. Duncan,et al. Preclinical toxicology of a novel polymeric antitumour agent: HPMA copolymerdoxorubicin (PK1) , 1998, Human & experimental toxicology.
[118] M. Dewhirst,et al. Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. , 2007, Cancer research.
[119] E. Sausville,et al. Targetable HPMA Copolymer–Aminohexylgeldanamycin Conjugates for Prostate Cancer Therapy , 2009, Pharmaceutical Research.
[120] C. McCormick,et al. Advances in the synthesis of amphiphilic block copolymers via RAFT polymerization: stimuli-responsive drug and gene delivery. , 2008, Advanced drug delivery reviews.
[121] W. Hennink,et al. Degradation Mechanism and Kinetics of Thermosensitive Polyacrylamides Containing Lactic Acid Side Chains , 2003 .
[122] S. Beg,et al. Dendrimers as novel systems for delivery of neuropharmaceuticals to the brain. , 2011, CNS & neurological disorders drug targets.
[123] D. Kerr,et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. , 2009, International journal of oncology.
[124] Y. Alnouti,et al. Pharmacokinetic and biodistribution studies of N-(2-hydroxypropyl)methacrylamide copolymer-dexamethasone conjugates in adjuvant-induced arthritis rat model. , 2010, Molecular pharmaceutics.
[125] Jinming Gao,et al. Multifunctional Micellar Nanomedicine for Cancer Therapy , 2009, Experimental biology and medicine.
[126] F. Roelfsema,et al. Nanomedicines in the treatment of acromegaly: focus on pegvisomant , 2006, International journal of nanomedicine.
[127] C. Allen,et al. Poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: synthesis, characterization, and the influence of the drug on micelle morphology. , 2010, Biomacromolecules.
[128] F. Szoka,et al. Design, synthesis, and biological evaluation of a robust, biodegradable dendrimer. , 2010, Bioconjugate chemistry.
[129] Tao Wang,et al. Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity. , 2010, Molecular pharmaceutics.
[130] K. Ulbrich,et al. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[131] A. Chilkoti,et al. Temperature sensitive peptides: Engineering hyperthermia-directed therapeutics , 2008, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[132] Lei Yu,et al. Physicochemical properties and biocompatibility of a polymer-paclitaxel conjugate for cancer treatment , 2011, International journal of nanomedicine.
[133] S. V. Vinogradov,et al. Water-soluble block polycations as carriers for oligonucleotide delivery. , 1995, Bioconjugate chemistry.
[134] K. Ulbrich,et al. Preclinical evaluation of polymer-bound doxorubicin , 1992 .
[135] L. Murray,et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[136] R. Strickley. Solubilizing Excipients in Oral and Injectable Formulations , 2004, Pharmaceutical Research.
[137] K. Ulbrich,et al. HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release. , 2010, Molecular pharmaceutics.
[138] A. S. Moses,et al. Imaging and drug delivery using theranostic nanoparticles. , 2010, Advanced drug delivery reviews.
[139] Chi-Hwa Wang,et al. Polymeric carriers for gene delivery: chitosan and poly(amidoamine) dendrimers. , 2010, Current pharmaceutical design.
[140] T. Xu,et al. Dendrimers as drug carriers: applications in different routes of drug administration. , 2008, Journal of pharmaceutical sciences.
[141] A. Ray,et al. Carboxyl-terminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation. , 2010, Bioconjugate chemistry.
[142] S. Goldring,et al. Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis , 2007, Arthritis research & therapy.
[143] H. Ghandehari,et al. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[144] A. Chilkoti,et al. Expression and purification of recombinant proteins from Escherichia coli: Comparison of an elastin‐like polypeptide fusion with an oligohistidine fusion , 2004, Protein science : a publication of the Protein Society.
[145] Y. Yoshioka,et al. The use of PVP as a polymeric carrier to improve the plasma half-life of drugs. , 2004, Biomaterials.
[146] Yosuke Suzuki,et al. Lactoferrin Conjugated with 40-kDa Branched Poly(ethylene Glycol) Has an Improved Circulating Half-Life , 2009, Pharmaceutical Research.
[147] Allan S Hoffman,et al. Poly(N-isopropylacrylamide-co-propylacrylic acid) copolymers that respond sharply to temperature and pH. , 2006, Biomacromolecules.
[148] Thommey P. Thomas,et al. Targeting and inhibition of cell growth by an engineered dendritic nanodevice. , 2005, Journal of medicinal chemistry.
[149] J. Kopeček,et al. Enantioselective release of 5-fluorouracil from N-(2-hydroxypropyl)methacrylamide-based copolymers via lysosomal enzymes. , 1995, Bioconjugate chemistry.
[150] T. Okano,et al. Preparation of micelle-forming polymer-drug conjugates. , 1992, Bioconjugate chemistry.
[151] A. Ray,et al. Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[152] L. Murray,et al. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours , 1999, British Journal of Cancer.
[153] H. Zhao,et al. 20-O-acylcamptothecin derivatives: evidence for lactone stabilization. , 2000, The Journal of organic chemistry.
[154] M. Graham. Pegaspargase: a review of clinical studies. , 2003, Advanced drug delivery reviews.
[155] K. Ulbrich,et al. Poly(ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin. , 2000, Bioconjugate chemistry.
[156] Francesco M Veronese,et al. Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. , 2002, Advanced drug delivery reviews.
[157] A. Seligman,et al. Polyvinyl pyrrolidone as a plasma expander; studies on its excretion, distribution and metabolism. , 1952, The New England journal of medicine.
[158] Z. Lu,et al. Synthesis and characterization of HPMA copolymer-aminopropylgeldanamycin conjugates. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[159] Wim E Hennink,et al. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[160] Y. Ikada,et al. Targeted delivery of anti-angiogenic agent TNP-470 using water-soluble polymer in the treatment of choroidal neovascularization. , 1999, Investigative ophthalmology & visual science.
[161] Jan Jezek,et al. Peptide and glycopeptide dendrimers and analogous dendrimeric structures and their biomedical applications , 2011, Amino Acids.
[162] P. Okunieff,et al. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.
[163] P. Ofek,et al. A novel antitumor prodrug platform designed to be cleaved by the endoprotease legumain. , 2009, Bioconjugate chemistry.
[164] Donald A Tomalia,et al. Dendrimers in biomedical applications--reflections on the field. , 2005, Advanced drug delivery reviews.
[165] Chen Jiang,et al. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. , 2009, Biomaterials.
[166] Ashutosh Chilkoti,et al. Targeted drug delivery by thermally responsive polymers. , 2002, Advanced drug delivery reviews.
[167] Todd Emrick,et al. PEGylated polymers for medicine: from conjugation to self-assembled systems. , 2010, Chemical communications.
[168] Veronese Fm,et al. Introduction and overview of peptide and protein pegylation. , 2002 .
[169] W. Hennink,et al. Reduction-sensitive polymers and bioconjugates for biomedical applications. , 2009, Biomaterials.
[170] I. Orienti,et al. Modified Doxorubicin for Improved Encapsulation in PVA Polymeric Micelles , 2004, Drug delivery.
[171] J. Kopeček,et al. HPMA copolymers: origins, early developments, present, and future. , 2010, Advanced drug delivery reviews.
[172] Markéta Jelínková,et al. Starlike vs. Classic Macromolecular Prodrugs: Two Different Antibody-Targeted HPMA Copolymers of Doxorubicin Studied in Vitro and in Vivo as Potential Anticancer Drugs , 2003, Pharmaceutical Research.
[173] C. Ryan,et al. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy , 2010, Anti-cancer drugs.
[174] Gert Storm,et al. Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release , 2010, Pharmaceutical Research.
[175] D. Wyss,et al. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. , 2002, Advanced drug delivery reviews.
[176] M. Stenzel,et al. The use of reversible addition fragmentation chain transfer polymerization for drug delivery systems , 2011, Expert opinion on drug delivery.
[177] V. Torchilin,et al. Structure and design of polymeric surfactant-based drug delivery systems. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[178] J. Kopeček,et al. Biodegradable Multiblock Poly[N-(2-hydroxypropyl)methacrylamide] via Reversible Addition-Fragmentation Chain Transfer Polymerization and Click Chemistry. , 2011, Macromolecules.
[179] R. Kannan,et al. Transfer of PAMAM dendrimers across human placenta: prospects of its use as drug carrier during pregnancy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[180] M. Brechbiel,et al. Growing applications of "click chemistry" for bioconjugation in contemporary biomedical research. , 2009, Cancer biotherapy & radiopharmaceuticals.
[181] K. Ulbrich,et al. Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[182] Ruth Duncan,et al. Anionic PAMAM Dendrimers Rapidly Cross Adult Rat Intestine In Vitro: A Potential Oral Delivery System? , 2000, Pharmaceutical Research.
[183] Khaled Greish,et al. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines , 2007, Journal of drug targeting.
[184] J. Kopeček,et al. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers. , 1985, Biomaterials.
[185] F. Kiessling,et al. Macromolecular nanotheranostics for multimodal anticancer therapy. , 2011, Nanoscale.
[186] K. Ulbrich,et al. HPMA-based polymer conjugates with drug combination. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[187] A. Pineda-Lucena,et al. Polymer coiled-coil conjugates: potential for development as a new class of therapeutic "molecular switch". , 2011, Biomacromolecules.
[188] Ashutosh Chilkoti,et al. Purification of recombinant proteins by fusion with thermally-responsive polypeptides , 1999, Nature Biotechnology.
[189] H. Byrne,et al. Mechanistic studies of in vitro cytotoxicity of poly(amidoamine) dendrimers in mammalian cells. , 2010, Toxicology and applied pharmacology.
[190] Zhongfan Jia,et al. One-pot conversion of RAFT-generated multifunctional block copolymers of HPMA to doxorubicin conjugated acid- and reductant-sensitive crosslinked micelles. , 2008, Biomacromolecules.
[191] Patricia Kraft,et al. Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model , 2008, Clinical Cancer Research.
[192] J. Leroux,et al. Synthesis and Micellar Characterization of Novel Amphiphilic A−B−A Triblock Copolymers of N-(2-Hydroxypropyl)methacrylamide or N-Vinyl-2-pyrrolidone with Poly(ε-caprolactone) , 2002 .
[193] T. Xu,et al. Design, synthesis and potent pharmaceutical applications of glycodendrimers: a mini review. , 2007, Current drug discovery technologies.
[194] K. Ulbrich,et al. Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[195] Deborah S. Goldberg,et al. Cellular Entry of G3.5 Poly (amido amine) Dendrimers by Clathrin- and Dynamin-Dependent Endocytosis Promotes Tight Junctional Opening in Intestinal Epithelia , 2010, Pharmaceutical Research.
[196] V. Galic,et al. Paclitaxel poliglumex for ovarian cancer , 2011, Expert opinion on investigational drugs.
[197] Jeong Yu Lee,et al. Intracellular delivery of paclitaxel using oil-free, shell cross-linked HSA--multi-armed PEG nanocapsules. , 2011, Biomaterials.
[198] M. S. Tewart,et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. , 2000 .
[199] D. Appelhans,et al. In vivo toxicity of poly(propyleneimine) dendrimers. , 2011, Journal of biomedical materials research. Part A.